We commit resources and expertise for poorly-understood diseases.
Tens of millions of people worldwide suffer every year from known and emerging infectious diseases that have few therapeutic options, both in the developing world and more recently due to global pandemic illness.
At Ridgeback, we commit resources and expertise for undefined and poorly understood diseases early in the pharmaceutical development cycle, at a time generally when few stakeholders are prepared to make the necessary commitments.
- Press Release / Business Wire 10.20.2021
- Media / CNBC, Squawk on the Street 10.01.2021
- Media / The Wall Street Journal 12.20.2021